3 Nov 2023 | News
Technophage is thrilled to share that TZ-161 product is now one step closer to potentially becoming a pioneering repurposed treatment for patients suffering from acute spinal cord injury. This innovative product, currently undergoing clinical trial application in...
22 Set 2023 | News
Miguel Garcia, the CEO of Technophage S.A. and LxBio – Pharmaceuticals S.A., recently presented the Bio-Hub Project during the First Annual Meeting of Mobilizing and Green Agendas for Business Innovation, as part of the Recovery and Resilience Plan (PRR). The...
20 Set 2023 | News
This week marked an important occasion as Technophage and VectorB2B – Drug Development joined forces for our annual Teambuilding event. Our destination was the picturesque town of Dornes, where a selection of thrilling team challenges awaited us. Both teams...
10 Mai 2023 | News
Last month Technophage team attended 33rd European Congress of Clinical Microbiology & Infectious Diseases with the clinical team from Israel, and Dr. Ran Nir-Paz from Hadassah Medical Center, presented the results obtained in the Phase I/IIa double-blinded,...
8 Mai 2023 | News
Technophage has been featured in ‘The Economist’ journal. The piece entitled ‘Western firms are becoming interested in a Soviet medicine’ describes how phage therapy is helping patients around the globe, highlighting the increased interest of western...
